论文部分内容阅读
目的观察罗格列酮对两肾一夹高血压大鼠的降压作用,并探讨其与调节糖脂代谢的关系。方法两肾一夹高血压大鼠24只,随机分为未治疗组(2K1C)、罗格列酮5mg·kg-1·d-1组(RGL5)、罗格列酮20mg·kg-1·d-1组(RGL20)。另设一假手术组(SHAM)作为空白对照。每2周测一次收缩压、体重,共观察10周。干预前后采空腹静脉血查血清胆固醇、三酰甘油及葡萄糖。结果干预结束时,与2K1C组收缩压比,RGL5组无差异,RGL20组第二周开始降低(P<0.05);与2K1C组三酰甘油水平比,RGL5组、RGL20组均较低(P<0.05),但后两组之间三酰甘油水平无差异。结论罗格列酮5mg·kg-1·d-1对2K1C大鼠有降三酰甘油作用,但无降压作用。罗格列酮20mg·kg-1·d-1对2K1C大鼠有降三酰甘油作用,亦有降压作用,但其降压作用可能不完全依赖于其调节糖脂代谢的作用。
Objective To observe the antihypertensive effects of rosiglitazone on two kidneys and one clip hypertensive rats and to explore its relationship with the regulation of glucose and lipid metabolism. Methods Twenty-four hypertensive rats with two kidneys and one clip were randomly divided into untreated group (2K1C), rosiglitazone 5 mg · kg-1 · d-1 group (RGL5), rosiglitazone 20 mg · kg-1 · d-1 group (RGL20). Another sham operation group (SHAM) as a blank control. Systolic blood pressure was measured every 2 weeks and the body weight was observed for 10 weeks. Serum cholesterol, triglyceride and glucose were collected from the ventral venous blood before and after intervention. Results Compared with the 2K1C group, the RGL5 group and the 2K1C group had no significant difference compared with the 2K1C group (P <0.05). Compared with the 2K1C group, the RGL5 group and the RGL20 group were lower (P < 0.05), but there was no difference in triglyceride between the latter two groups. Conclusion Rosiglitazone 5mg · kg-1 · d-1 has hypoglyceridyl activity on 2K1C rats, but no antihypertensive effect. Rosiglitazone 20mg · kg-1 · d-1 has hypotensive effect on 2K1C rats, but antihypertensive effect may not be completely dependent on its regulation of glucose and lipid metabolism.